Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Seibold

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Inflammatory Bowel Diseases|June 16, 2011
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II surveyStephan R Vavricka, Alain M Schoepfer, Georg Bansky, et al.
Plos One|November 19, 2011
Enhanced activity of meprin-α, a pro-migratory and pro-angiogenic protease, in colorectal cancerDaniel Lottaz, Christoph A Maurer, Agnès Noël, et al.
Frontiers in Immunology|June 9, 2020
Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human NeutrophilsStefanie Graeter, Christoph Schneider, Daniëlle Verschoor, et al.
Digestive Diseases (Basel, Switzerland)|June 9, 2017
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III SurveyStephan R Vavricka, Milos Spasojevic, Gerhard Rogler, et al.
Nutrients|December 17, 2024
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled TrialLuc Biedermann, Michael Doulberis, Philipp Schreiner, et al.
Inflammatory Bowel Diseases|May 29, 2015
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease CohortStephan R Vavricka, Gerhard Rogler, Claudine Gantenbein, et al.
Inflammatory Bowel Diseases|April 29, 2017
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort StudyStephan R Vavricka, Martin Gubler, Claudine Gantenbein, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 3, 2020
IgA Triggers Cell Death of Neutrophils When Primed by Inflammatory MediatorsMarc Wehrli, Christoph Schneider, Fabiola Cortinas-Elizondo, et al.
Gut|October 5, 2013
Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel diseaseIsabelle Cleynen, Emilie Vazeille, Marta Artieda, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Inflammatory Bowel Diseases|June 16, 2011
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II surveyStephan R Vavricka, Alain M Schoepfer, Georg Bansky, et al.
Plos One|November 19, 2011
Enhanced activity of meprin-α, a pro-migratory and pro-angiogenic protease, in colorectal cancerDaniel Lottaz, Christoph A Maurer, Agnès Noël, et al.
Frontiers in Immunology|June 9, 2020
Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human NeutrophilsStefanie Graeter, Christoph Schneider, Daniëlle Verschoor, et al.
Digestive Diseases (Basel, Switzerland)|June 9, 2017
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III SurveyStephan R Vavricka, Milos Spasojevic, Gerhard Rogler, et al.
Nutrients|December 17, 2024
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled TrialLuc Biedermann, Michael Doulberis, Philipp Schreiner, et al.
Inflammatory Bowel Diseases|May 29, 2015
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease CohortStephan R Vavricka, Gerhard Rogler, Claudine Gantenbein, et al.
Inflammatory Bowel Diseases|April 29, 2017
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort StudyStephan R Vavricka, Martin Gubler, Claudine Gantenbein, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 3, 2020
IgA Triggers Cell Death of Neutrophils When Primed by Inflammatory MediatorsMarc Wehrli, Christoph Schneider, Fabiola Cortinas-Elizondo, et al.
Gut|October 5, 2013
Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel diseaseIsabelle Cleynen, Emilie Vazeille, Marta Artieda, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Pageof 8